QT Imaging Holdings (QTI) Q4 2024 earnings summary

Executive summary

• Achieved $4.9 million in commercial revenue for 2024, up from less than $0.1 million in 2023, with twelve scanners shipped in 2024 compared to none in 2023.

• Gross margin improved to 54% for 2024, compared to a negative margin in 2023.

• Net loss for 2024 was $9.0 million, including significant non-cash and one-time items.

• Completed PIPE investment of $2.56 million and secured a $10.1 million term loan, using proceeds to clear all short-term debt.

• Entered strategic agreements with NXC Imaging for distribution and Canon Medical Systems for manufacturing scale-up.

Financial highlights

• Q4 2024 revenue was $0.8 million, down from $1.0 million in Q3 2024 but up from less than $0.1 million in Q4 2023.

• Gross margin was 47% in Q4 2024, down from 63% in Q3 2024, due to inventory cost variability.

• Adjusted EBITDA for 2024 was $(7.3) million, compared to $(2.9) million in 2023.

• Net cash used in operating activities was $10.0 million for 2024, up from $2.7 million in 2023.

• Basic and diluted net loss per share for 2024 was $(0.71), compared to $(0.64) in 2023.

Outlook and guidance

• Forecasts revenue of $18 million in 2025 (40 scanners) and $27 million in 2026 (60 scanners), in line with minimum order quantities in the amended NXC Imaging agreement.

• Strategic partnerships and manufacturing agreements position the company for scalable growth in the breast imaging market.